In Episode 38 of Hims House, Jonathan Stern and Patrick Lester (Bayside) break down all the recent news surrounding Hims. They cover the new Bloomberg Businessweek article and Washington Post coverage, discuss Hims’ expansion into Canada with generic semaglutide, and highlight the company’s recent job listing for a new blood diagnostics vertical. The episode closes with an analysis of Hims’ positioning ahead of earnings. They unpack alt data trends, app rankings, web traffic discrepancies, and Google Trends.
00:52 Bloomberg Businessweek Story Analysis
03:45 Hims Expansion into Canada
09:00 Washington Post Story and the Novo Deal Collapse
24:40 New Blood Diagnostics Vertical
29:17 Andrew Responds to Nighthawk: "🤣"
31:00 Hims Alt Data Recap
31:39 Morgan Stanley's Note on App Deceleration
32:08 Web Traffic
34:02 GLP-1 Contribution and Revenue Impact
46:17 Advertising
01:00:14 Short Interest Hits 38%
Get full access to Hims House at
himshouse.substack.com/subscribe
